Education
About Us
Working with TipRanks
Follow Us
Septerna, Inc. (SEPN)
:SEPN
SEPN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.17 - $28.99
Previous CloseN/A
Volume49.14K
Average Volume (3M)803.67K
Market Cap
$272.63M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)710.00K
Price to Earnings (P/E)―
Beta3.43
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding44,402,740
10 Day Avg. Volume279,943
30 Day Avg. Volume803,666
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1740.82
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$14.00Price Target Upside129.51% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Septerna, Inc. News
PremiumCompany Announcements
Septerna, Inc. Shifts Focus to Next-Gen PTH1R Agonist
---
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentSepterna focuses on validated targets in large established indications, where an oral option presents a clear benefit to patients.
Financial PerformanceSEPN ended 3Q24 with ~$440MM in pro forma cash post IPO, which the company believes provides cash runway into 2H27.
Technology And InnovationSepterna is developing novel oral small molecule GPCR-targeted drugs, utilizing a proprietary technology that captures GPCRs in their native conformational states.
Bears Say
Development UncertaintyA new development candidate for the PTH program has not been selected, leading to a removal of value from the program.
Lack Of CatalystsThe company is essentially a preclinical stage biotech with the lack of catalysts in the next 12-18 months.
Program DiscontinuationSEPN plans to discontinue their SEP-786 program due to unanticipated increases in unconjugated serum bilirubin.
---
Ownership Overview
24.41% Insiders
0.29% Mutual Funds
― Other Institutional Investors
73.30% Public Companies and
Individual Investors
SEPN FAQ
What was Septerna, Inc.’s price range in the past 12 months?
Septerna, Inc. lowest stock price was $4.17 and its highest was $28.99 in the past 12 months.
What is Septerna, Inc.’s market cap?
Septerna, Inc.’s market cap is $272.63M.
When is Septerna, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Septerna, Inc.’s earnings last quarter?
Septerna, Inc. released its earnings results on Nov 20, 2024. The company reported -$8.4 earnings per share for the quarter, missing the consensus estimate of -$5.877 by -$2.523.
Is Septerna, Inc. overvalued?
According to Wall Street analysts Septerna, Inc.’s price is currently Undervalued.
Does Septerna, Inc. pay dividends?
Septerna, Inc. does not currently pay dividends.
What is Septerna, Inc.’s EPS estimate?
Septerna, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Septerna, Inc. have?
Septerna, Inc. has 44,402,740 shares outstanding.
What happened to Septerna, Inc.’s price movement after its last earnings report?
Septerna, Inc. reported an EPS of -$8.4 in its last earnings report, missing expectations of -$5.877. Following the earnings report the stock price went down -7.025%.
Which hedge fund is a major shareholder of Septerna, Inc.?
Currently, no hedge funds are holding shares in SEPN
---
Septerna, Inc. Stock Smart Score
Company Description
Septerna, Inc.
Septerna, Inc. (SEPN) is a biotechnology company focused on the discovery and development of small molecule drugs targeting G protein-coupled receptors (GPCRs). Operating within the pharmaceutical and biotechnology sectors, Septerna leverages its proprietary technology to identify novel therapeutic candidates aimed at addressing unmet medical needs across various disease areas.
---
SEPN Stock 12 Month Forecast
Average Price Target
$14.00
▲(129.51% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Biogen
―
Ionis Pharmaceuticals
―
Regeneron
―
Vertex Pharmaceuticals
―
Best Analysts Covering SEPN
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-74.60%
reiterated a buy rating yesterday
Copying Yaron Werber's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -74.60% per trade.
---